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Objective. +e effect of pulmonary vein isolation (PVI) on fibrinolytic and endothelial activation with currently applied peri-
procedural anticoagulation has not been explored. Wemeasured markers of fibrinolysis and endothelium activation before and after
PVI with the second-generation cryoballoon (Cryo), pulmonary vein ablation catheter (PVAC-Gold), and irrigated radiofrequency
(IRF). Methods. Markers of fibrinolysis and endothelium activation in left atrial (LA) blood samples were measured in 31 patients
before and after PVI (Cryo:10, PVAC-Gold: 7, IRF: 14). Periprocedural anticoagulation included uninterrupted vitamin K antagonist
and iv heparin (ACT≥300 sec) during LA dwelling. Results. Levels ofD-dimer (median; interquartile range, mgFEU/L) increased with
all techniques (PVAC: 0.34; 0.24–0.50 versus 0.70; 0.61–1.31; p � 0.0313, Cryo: 0.33; 0.28–0.49 versus 0.79; 0.65–0.93; p � 0.0078;
IRF 0.33; 0.21–0.44 versus 0.83; 0.56–1.21; p � 0.0001). PAP complex level (ng/ml) increased after Cryo (247.3, 199.9–331.6 versus
270.9, 227.9–346.7; p � 0.0020) and IRF (265.3; 202.0–800.1 versus 325.6, 250.2–701.9; p � 0.0166), but not after PVAC
(p � 0.2969). PAI-1 activity (%) decreased with the PVAC (1.931; 0.508–3.859 versus 0.735, 0.240–2.707; p � 0.0313) and Cryo
(0.361; 0.080–1.575 versus 0.378; 0.111–0.915; p � 0.0313). A similar trend was observed with IRF (p � 0.0676). Both VWF antigen
levels and FVIII activity increased after PVI with all the 3 techniques. +e levels of soluble VCAM-1 (ng/ml) did not change after
PVAC procedures, but increased after Cryo (542, 6; 428.5–753.1 versus 619.2; 499.8–799.0; p � 0.0005) and IRF (679.3; 505.0–744.7
versus 770.9; 631.9–894.0; p< 0.0001). Conclusion. PVI with contemporary ablation techniques and periprocedural antithrombotic
treatment induces coagulation and endothelium activation of similar magnitude with different ablation methods.
1. Introduction
Pulmonary vein isolation (PVI) is an established therapy for
the management of atrial fibrillation (AF) with a low risk of a
major complication, including thromboembolism [1–3].
Available data indicate that the risk of a clinical or a silent
thromboembolic event is related to the periprocedural
anticoagulation routine and the ablation technology used
[4–7]. +e interaction between coagulation activation and
the different maneuvers and techniques used during an AF
ablation procedure is not fully understood. Earlier studies
mostly on patients undergoing radiofrequency (RF) ablation
for paroxysmal supraventricular tachycardia suggested that
the coagulation cascade is activated by the introduction of
any instrumentation (sheath, catheter) into the bloodstream,
and conflicting results were published on the role of RF
applications per se [8–11]. It has also been proposed that
thrombogenesis related to catheter ablation is a 2-phase
response: the acute phase during the procedure is mostly
related to catheter insertion in the bloodstream and the 2nd
phase is due to the tissue damage created by the ablation
itself [12]. +ese earlier studies involved a relatively low
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number of RF deliveries confined to a physically limited
region in the heart. On the contrary, a large area is covered
within the left atrium with circumferential lesions placed
around all pulmonary veins (PVs) during AF ablation, which
poses a potentially more significant effect on coagulation and
endothelial activation. Limited data are available on intra-
cardiac hemostasis activation in response to the endothelial
damage with contemporary AF ablation technologies and
periprocedural anticoagulation routine.
Previously, our group compared hemostasis markers in
blood samples obtained from the femoral vein, from the left
atrium, and from the left atrial appendage in patients with AF
versus in those undergoing left atrial catheterization for an-
other substrate. +e aim of this earlier work was to explore
potential site-specific differences in coagulation activation as
well as the differences in patients with versus without AF [13].
Herein, we measured the levels of different fibrinolytic and
endothelial activation markers in left atrial blood samples
before and after PVI to assess to effect of the ablation per se.
Further, we compared these changes obtained with 3 different
ablation technologies. +ese included electroanatomically
guided point-by-point focal irrigated RF ablation with contact
force monitoring considered bymany as the “gold standard” of
AF ablation, and 2 of the “single-shot” technologies: cryoa-
blation with the 2nd-generation cryoballoon catheter (Arctic
Front Advance) and phased RF ablation with the modified
circular pulmonary vein ablation catheter (PVAC-Gold).
2. Methods
2.1. Study Population. Consecutive patients undergoing
radiofrequency ablation for symptomatic paroxysmal or
persistent AF were enrolled in the study based on the fol-
lowing: age 18–75 years, documented, symptomatic par-
oxysmal or persistent AF, failure of at least one
antiarrhythmic drug, and willingness to sign a written in-
formed consent. Exclusion criteria included long-standing
persistent AF, reversible cause of AF (e.g. hyperthyroidism),
presence of a left atrial thrombus, previous heart surgery,
valvular heart disease, left ventricular ejection fraction
(LVEF) ≤30%, heart failure of New York Heart Association
functional classification (NYHA) class III or IV, docu-
mented carotid stenosis, history of ischemic stroke or TIA,
prior cardiac surgery, unstable angina or myocardial in-
farction within the last 3 months, severe chronic obstructive
pulmonary disease, known bleeding or thrombotic disor-
ders, acute inflammation, contraindication to oral anti-
coagulation, and pregnancy.
+e study design was in accordance with the guiding
principles of the Declaration of Helsinki and was approved
by the Institutional Ethics Committee of the University of
Debrecen and the Ethics Committee of the National Medical
Research Council. All patients signed a written informed
consent form prior to inclusion.
2.2. Catheter Placement and AF Ablation Procedure. All
procedures were performed on uninterrupted vitamin K
antagonist (VKA) therapy to maintain a therapeutic INR
level between 2-3, which was confirmed on the morning of
the procedure in line with recent guideline recommenda-
tions [14]. All medications with a potential effect on platelet
activity were discontinued for a period of at least three half-
lives before the procedure. Transesophageal echocardiog-
raphy was carried out within 24 hours prior to the procedure
in order to rule out the presence of a cardiac thrombus.
Procedures were carried out under conscious sedation, using
midazolam and fentanyl. +ree punctures of the right
femoral vein were performed using the Seldinger technique
and introducers with side arms were placed in the vein. A
multipolar electrode catheter was placed in the coronary
sinus and an intracardiac echocardiography (ICE) catheter
in the right atrium to guide transseptal puncture and po-
sitioning of the ablation catheter with any of the 3 tech-
nologies used (see below). Fluoroscopy- and ICE-guided
transseptal puncture was performed with a Brockenbrough
needle. Immediately after transseptal puncture and prea-
blation blood sample collection from the left atrium (LA), a
150-IU/kg body weight intravenous heparin bolus was given,
followed by a continuous infusion to maintain a minimum
target ACT level above 300ms. LA sheaths were flushed
continuously with heparinized saline at a steady rate around
30ml/h, and additional fluid replacement was allowed in
case of hypotonia throughout the procedure.
All PVI procedures were performed with any of 3 ab-
lation technologies: 1, PVAC group: phased RF ablation with
the second-generation PVAC-Gold catheter; 2, Cryo group:
cryoablation with the second-generation Arctic Front Ad-
vance catheter; 3, IRF group: focal irrigated radiofrequency
ablation with contact force monitoring using a +ermocool,
Smarttouch catheter under guidance with the CARTO
Merge 3-D electroanatomical mapping system. +e choice
between these ablation methods was based on operator and
patient preference. Regardless of the ablation technology
used, procedural endpoint was PVI, defined as PV-LA en-
trance block verified with pacing maneuvers according to
standard practice. Sinus rhythm (SR) was restored by car-
dioversion at the end of the procedure as needed.
2.3. Phased RF Ablation (PVAC Group). Phased RF ablation
protocol at our center and technical details of the 2nd-
generation PVAC have been described earlier [15, 16].
Briefly, the Mullins sheath was exchanged for a deflectable
12-Fr long FlexCath sheath and advanced into the LA over a
220 cm guidewire. Submerged loading of the circular PVAC-
Gold containing 9 electrodes of gold alloy into the intro-
ducer as well as continuous flushing of the sheath with
heparinized saline was performed to minimize air ingress.
Duty-cycled bipolar and unipolar phased RF energy to all or
selected electrode pairs was delivered in a temperature-
controlled and power-limited fashion (60°C, maximum
10W) with typical ablation duration of 60 s. Pulmonary
veins (PVs) were electrically isolated by targeted ablation of
each PV-LA antrum.
2.4. Cryoballoon Ablation (Cryo Group). Our ablation pro-
tocol and technical details of the 2nd-generation Arctic Front
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Advance catheter have been described [16, 17]. Briefly, the
Mullins sheath was exchanged for the deflectable 12-Fr long
FlexCath sheath and advanced into the LA over a stiff long
guidewire. +e 28-mm Arctic Front Advance balloon was
used in all cases. An 8-pole, circular electrode catheter was
advanced through the lumen of the cryoballoon and used as
a guidewire to cannulate specific side branches of the PVs to
allow continuous monitoring of PV electrograms during
each freezing cycle. +e balloon was manipulated to obtain
the possibly most antral position with still a good seal of the
vein as assessed by contrast injection and ICE Doppler. Two
freezing cycles of 3–4 minutes in duration were usually
applied in each PV based on the achieved temperature and
the time to PVI. Temperature between − 40°C and − 55°C was
considered as appropriate, and cryoapplication was termi-
nated in case of lower value to minimize the risk of collateral
damage.
2.5. Point-by-Point Pulmonary Vein Isolation with Irrigated
Radiofrequency Ablation (IRF Group). After 2 separate
transseptal punctures, a Mullins transseptal and a 9 F
steerable Agilis sheath were placed in the LA. A circular
decapolar Lasso catheter and a contact force ablation
catheter were advanced through the Mullins and the Agilis
sheath, respectively. A 3D anatomical map of the LA was
obtained using the Carto Merge System®. Predefined linesfor the ablation circles were tagged in the antrum of the PVs.
Point-by-point IRF ablation was performed isolating the left
and the right PVs in separate circles. RF energy was delivered
in power-controlled mode without ramping using 30–35W
on anterior segments and 20–25W on posterior wall with an
irrigation flow of 17 cc/min. Energy was delivered for 30 s at
each site after obtaining a target contact force >6 g. Ablation
tags were displayed using Visitag® (Biosense-Webster Inc,Diamond Bar, CA, USA). PVI in each PV was assessed based
on signals recorded through electrodes of the Lasso catheter.
2.6. Blood Sampling and Laboratory Investigations.
Preablation blood samples were taken from the LA through
the Mullins sheath immediately after transseptal puncture
and removal of the dilator, before the intravenous admin-
istration of unfractionated heparin. Postablation blood
samples were collected through the LA sheath after removal
of the ablation catheter once the last ablation was finished.
Forty-five ml blood samples were drawn from which the first
15ml of blood was discarded in order to exclude intrasheath
hemostasis activation [13]. Blood samples were collected
into vacutainer tubes (tubes containing 0.109M sodium
citrate), tubes containing CTAD (buffered citrate, theoph-
ylline, adenosine, and dipyridamole), and tubes containing
no anticoagulant (serum tubes with polymer gel separator,
SST; Becton Dickinson, Franklin Lakes, NJ). Anticoagulated
blood samples were centrifuged twice at 1500 g, and SST
tubes were centrifuged once at 2000 g, at room temperature
for 20min. Plasma and serum samples were stored at − 70°C
until further analysis. +e measurement of plasminogen
activator inhibitor-1 (PAI-1) activity was performed from
plasma samples anticoagulated with CTAD; besides this
measurement, all hemostasis and fibrinolysis tests were
performed using citrated plasma. Screening tests of hemo-
stasis (prothrombin time, activated partial thromboplastin
time, and thrombin time) were performed from freshly
separated plasma samples using routine methods (Siemens
Healthcare Diagnostic Products, Marburg, Germany).
Commercially available ELISA tests were used to determine
PAI-1 activity (Technozym PAI-1 Actibind, Technoclone,
Vienna, Austria) and plasmin-α2-antiplasmin (PAP) com-
plex (Technozym PAP complex ELISA kit, Technoclone,
Vienna, Austria). Factor VIII (FVIII) activity using a
chromogenic assay, von Willebrand factor (VWF) antigen
level, and D-dimer levels were measured on a BCS coa-
gulometer by standard methods (Siemens Healthcare Di-
agnostic Products, Marburg, Germany). sVCAM-1 levels
were measured from the stored serum samples using ELISA
(Quantikine ELISA human sVCAM-1/CD106 Immunoas-
say, R&D Systems Europe Ltd, Abingdon). Albumin levels of
all serum samples were quantified using standard methods
(Roche, Basel, Switzerland). All measurements were cor-
rected to albumin levels measured at the time of blood
sampling before and after ablation in order to compensate
for plasma dilution as a consequence of fluid replacement
with saline during markedly different ablation times re-
quired by different ablation techniques.
2.7. Statistical Analysis. Statistical analysis was performed
using GraphPad Prism Software version 5.0 (La Jolla, CA)
and the Statistical Package for Social Sciences (SPSS, Release
22.0, Chicago, IL). Normality of the data was evaluated by
the D’Agostino and Pearson omnibus normality test. A
paired t-test or Wilcoxon matched-pairs rank-sum test was
applied for comparing results obtained from preablation and
postablation intracardiac samples. ANOVA with Bonferroni
post hoc test or Kruskal–Wallis test using Dunn–Bonferroni
post hoc test was applied for multiple comparisons of un-
paired data. Differences between categorical variables were
assessed by the χ2 or Fisher’s exact test. p< 0.05 was con-
sidered statistically significant.
3. Results
3.1. Baseline Patient andProcedureCharacteristics. A total of
31 patients were included in the study (Table 1). PVI was
performed with phased RF in 7, with cryoballoon in 10, and
with point by point IRF ablation in14 patients. Acute PVI
was achieved in all PVs in all patients. No difference in
baseline characteristics was found between the 3 groups
regarding demographics, comorbidities, echocardiographic
parameters, and thromboembolic risk. Left atrial access
times were significantly longer with IRF ablation. No pro-
cedural complication occurred in any of the patients.
3.2. Fibrinolytic Parameters. Levels of D-dimer in left atrial
blood samples increased significantly after ablation with the
PVAC (p � 0.0313), cryo (p � 0.0078), and IRF (p � 0.0001;
Figure 1). Postablation values exceeded the cutoff value of
D-dimer (0.5mg FEU/L) with all 3 ablation modalities.
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Levels of PAP complex demonstrated no significant
change with phased RF ablation (p � 0.2969), but signifi-
cantly increased after cryo (p � 0.0020) and irrigated RF
(p � 0.0166; Figure 2). However, preablation and post-
ablation median PAP values did not exceed the cutoff value
proposed by the manufacturer.
PAI-1 activity decreased significantly during ablations
with the PVAC (p � 0.0313) and cryo (p � 0.0313). A
nonsignificant trend was observed with IRF (p � 0.0676;
Figure 3).
3.3. Parameters Related to Endothelial Damage. VWF anti-
gen levels increased significantly during ablations with all 3
types of catheters. Significant increase was observed after
PVAC ablation (p � 0.0313), after cryo ablation
(p � 0.0039), and a highly significant increase occurred after
IRF ablations (p � 0.0002; Figure 4).
+e increase in FVIII activity levels during the ablation
procedures was concordant with the increase in VWF an-
tigen levels. A significant elevation in FVIII activity was
observed after phased RF (p � 0.0355), after cryo
(p � 0.0078), and a highly significant elevation was found
after irrigated RF ablations (p � 0.0002; Figure 5).
+e levels of soluble VCAM-1 (ng/ml) were not sig-
nificantly different in the left atrium before and after the
PVAC procedure (p � 0.0963); however, significant increase
was detected after cryo (p � 0.0005) and also after IRF
(p< 0.0001; Figure 6).
4. Discussion
4.1. Fibrinolysis Activation during PVI. Limited data and
conflicting results are available on hemostasis activation
Table 1: Baseline parameters in patients undergoing pulmonary vein isolation with PVAC, Cryo, and IRF technologies. Continuous
variables are expressed as mean± SD or median (interquartile range). Categorical variables are indicated as number (percentage), unless
otherwise stated.
Variables PVAC (7) Cryo (n� 10) IRF (n� 14) p value
Age (years) 64.4 (59.9–69.4) 58.7 (48.4–65.6) 61.3 (55.3–65.1) 0.377
Male, n (%) 5 (71.43) 7 (70.00) 7 (50.00) 0.575
Left atrium size (mm) 43.14± 14 42.30± 3.30 42.00± 4.59 0.315
CHADS2-VASC score (mean) 2.29 1.50 2.36 0.514
INR on the day of the procedure 2.55± 0.46 2.35± 0.39 2.51± 0.45 0.208
LA access time (min) 75.00 (64.00–80.00) 83.00 (56.75–113.30) 150.00 (135.8–167.00) <0.001
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Figure 1: D-dimer levels measured from LA samples before (A)
and after (B) PVI with the PVAC, Cryo (cryoballoon), and IRF
techniques. Box and whisper plots indicate median, interquartile,
and total range. Dashed line indicates the upper limit of reference
interval. ∗p< 0.05; ∗∗p< 0.01; ∗∗∗p< 0.001.
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Figure 2: PAP complex levels measured before (A) and after (B)
PVI with the PVAC, Cryo, and IRF techniques. Box and whisper
plots indicate median, interquartile, and total range. ∗p< 0.05;∗∗p< 0.01; NS�nonsignificant.
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Figure 3: PAI-1 activity measured from LA blood samples before
(A) and after (B) PVI with the PVAC, Cryo, and IRF techniques.
Box and whisper plots indicate median, interquartile, and total
range. ∗p< 0.05.
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related to invasive electrophysiology procedures. Previous
studies evaluated fibrinolysis activation in blood samples
obtained from the femoral vein in patients undergoing RF
ablation for supraventricular tachycardias (SVTs). Dorbala
et al. [10] compared different markers of coagulation and
fibrinolytic activation measured in blood samples from the
femoral vein obtained immediately after sheath insertion,
after a diagnostic electrophysiology study (EPS), and after
RF ablation. Significant hemostasis activation was found
after EPS as compared to after sheath insertion but no
further increase postablation, suggesting that insertion of
foreign materials (sheaths, wires, and catheters) in the
bloodstream is a significant activator of coagulation. In
another report [11] on 37 patients, procedure duration, but
not the number of RF ablation, correlated with hemostasis
activation. On the contrary, Parizek et al. [9] reported a
significant elevation in D-dimer levels after diagnostic EPS
and which further increases after ablation. A statistical
correlation between D-dimer levels and the number of RF
applications was also demonstrated. Importantly, well-de-
fined, small-size substrates mainly in the right cardiac
chambers were targeted by the ablation in patients who were
not anticoagulated before the procedure in these studies.
Data on hemostasis activation related to AF ablation
were reported by Bulava et al. [18]: D-dimer levels dem-
onstrated a rapid elevation after sheaths and intracardiac
catheter placement with further increase after RF applica-
tions, which still persisted 24 hours after ablation.+is study
was carried out 15 years ago and thereby represents the AF
ablation routine of that time: nonirrigated focal RF lesions
were placed around or inside the PVs, vitamin K antagonist
was interrupted using low molecular weight heparin
bridging before the procedure, and intraprocedural heparin
applied according to activated partial thromboplastin time
(aPTI). Of note, blood samples in this investigation were also
obtained from the femoral vein.
As suggested by the results of these studies, insertion of
any foreign material into the blood stream initiates hemo-
stasis activation. Previously, our group measured hemostasis
activation in blood samples obtained sequentially from
different sites including the femoral vein, the left atrium, and
the left atrial appendage without any ablation therapy. In this
earlier work, which was completed in a different patient
cohort than the present study, we demonstrated that
transseptal puncture itself is a significant signal for further
hemostasis activation [13]. +e main focus of the present
study was to evaluate the effect of left atrial ablation per se;
therefore, blood samples were obtained from the LA before
the 1st and immediately after the last energy application.
Importantly, our periprocedural anticoagulation scheme
represented a common practice of AF ablation centers based
on recent guideline recommendations [14]. +is included
uninterrupted VKA with no bridging, INR level in the
therapeutic range before the procedure, and intravenous
administration of unfractionated heparin to maintain the
ACT level above 300 sec throughout catheter dwelling in the
LA. Despite these measures, significant coagulation activa-
tion was observed as indicated by the marked change in the
levels of different fibrinolysis markers. Postablation D-dimer
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Figure 5: Factor VIII activity measured from LA blood samples
before (A) and after (B) ablations with the PVAC, Cryo, and IRF
techniques. Box and whisper plots indicate median, interquartile,
and total range. ∗p< 0.05; ∗∗p< 0.01; ∗∗∗p< 0.001.
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Figure 6: sVCAM-1 levels measured from LA blood samples
before (A) and after (B) ablations with the PVAC, Cryo, and IRF
techniques. Box and whisper plots indicate median, interquartile,
and total range. ∗∗p< 0.01; ∗∗∗p< 0.001.
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Figure 4: von Willebrand factor antigen levels measured from LA
blood samples before (A) and after (B) ablations with the PVAC,
Cryo, and IRF techniques. Box and whisper plots indicate median,
interquartile, and total range. ∗p< 0.05; ∗∗p< 0.01; ∗∗∗p< 0.001.
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levels exceeded the normal cutoff value and elevated in the
range usually observed during clinical events related to
thrombus formation, such as deep vein thrombosis or
pulmonary embolism. +e levels of PAP complex increased
significantly after ablations with cryo and IRF but not with
the PVAC. As another indication of coagulation activation, a
significant decrease in PAI-1 activity was measured with
phased RF and cryo, and a trend for lower values was de-
tected after IRF ablations. +ese results suggest that sig-
nificant coagulation activation during AF ablation may not
be prevented with the anticoagulation scheme representing a
common practice of these days.
4.2. Endothelial Activation. Different ablation technologies
and ablation energy sources have different biophysical effect
on cardiac tissues. Kuhne et al. [19] measured significantly
higher levels of Troponin Tafter PVI using IRF as compared
to PVI with the 1st-generation cryoballoon. However, other
investigations comparing biomarkers of myocardial injury
after ablation reported conflicting results. In a multicenter
study [20], the highest creatinine kinase MB and troponin I
levels were demonstrated after PVI with cryoballoon as
compared to IRF with or without contact force and laser
ablation, while no difference in high sensitive troponin T,
microparticles, and high-sensitive CRP was found after PVI
with IRF versus with cryoballoon in another work [21]. +e
effect of various ablation technologies on endothelial acti-
vation has not been elucidated.
Endothelial damage is a known prothrombotic mecha-
nism as a component of Virchow’s triad. +e association
between left atrial appendage thrombus formation and
endocardial expression of VWF has been described [22].
Further, previous studies [18, 23] demonstrated that VWF
remains elevated for 24–48 hours after PVI with nonirri-
gated RF. Prolonged endothelial dysfunction might explain
previous observation that thromboembolism mostly occurs
within 48–72 hours after AF ablation in the majority of the
cases [2]. We demonstrated a significant increase in vWF
antigen and in FVIII activity levels with all 3 ablation
methods. Postablation elevation of sVCAM levels was as-
sociated with the use of cryoballoon and IRF, but not with
the PVAC. Overall, these results suggest that significant
endothelial damage is caused by contemporary ablation
techniques. +is finding highlights the importance of strict
and continuous anticoagulation in the postablation period.
4.3. Effect of Different AF Ablation Techniques on Hemostasis.
Due to the low incidence of thromboembolic events re-
lated to AF ablation, no data have been published on the
differential risk of this complication with different abla-
tion methods. Multiple groups reported on the incidence
of new silent cerebral ischemic lesions (SCI) detected by
DW-MRI after ablation, and rates as high as 50% were
published by some investigators [7, 24–27]. Although the
clinical significance of these usually small-sized white
matter lesions remains unknown, they were considered by
many as a potential surrogate for a clinical thrombo-
embolic event and thereby used to compare different
periprocedural anticoagulation schemes [28] and ablation
techniques. A higher rate of SCI with phased RF ablation
and the 1st-generation PVAC was a consistent finding in
multiple studies, while cryoablation appeared to be the
safest technique [24, 26, 27]. However, more recent
communications demonstrated that phased RF technol-
ogy became safer after procedural and technical modifi-
cations [14, 29–32]. We used state-of-the-art and
commonly applied AF ablation methods of these days: the
2nd generation of both the phased RF and the cryoballoon
technologies and irrigated RF catheters with contact force
measurement for point-by-point focal ablation. Although
with minor differences, similar effects on fibrinolytic and
endothelial activation were detected with any of them. In
line with published data [14, 16], LA access times were
significantly longer with focal irrigated RF ablation
compared with the single-shot technologies in our study;
therefore, the specific contribution of catheter dwelling in
the LA versus that of the RF energy applications on he-
mostasis activation could not be determined. +is might
be a relevant question with potential implications for
future innovations in AF ablation technology. Of note,
our ablation strategy included PVI alone, without any
other substrate modification technique, which would
result in more tissue damage, longer LA access time, and
potentially more marked hemostasis and endothelial
activation.
4.4. Potential Clinical Implications. Our results suggest that
antithrombotic treatment before AF ablation with widely
used techniques of these days needs to be improved for
patients’ safety. +e use of direct oral anticoagulants as a
substitute for uninterrupted VKA might be a promising
approach with supporting clinical data already available
[32–35]. Future studies on fibrinolysis and endothelial ac-
tivation related to the administration of these agents might
provide further insight regarding the mechanism of silent
and clinical embolic events. Measurement of these markers
might also be valuable to assess the risk of thromboembolic
complications involved with novel ablation technologies.
5. Limitations
+is was a nonrandomized study and patients were assigned
to 1 of 3 ablation methods according to their preference and
operator’s discretion. However, there were no significant
differences in baseline clinical parameters between treat-
ment groups. Uncertainties in the interpretation of fibri-
nolytic activation due to the longer LA access times with IRF
ablation remain as mentioned in the discussion. Our patient
population, similar to other publications on hemostasis
parameters, was relatively small. +is sample size may ex-
plain the minor inconsistencies in our results, that although
demonstrating similar trends, the change in the level of some
biomarkers did not reach the degree of statistical signifi-
cance. Further, the clinical significance of biomarker levels
during AF ablation and their use as surrogates of a clinical
thromboembolic event remain speculative.
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6. Conclusions
+is prospective observational study demonstrated that
significant fibrinolytic and endothelial activation is associ-
ated with currently used popular PVI ablation techniques
despite the use of periprocedural anticoagulation directed by
recent guidelines. No significant differences related to var-
ious ablation technologies could be demonstrated.
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